-
-
Pharma & Human Health -
Pharma & Human Health -
Pharma & Human Health -
Pharma & Human Health
Editor’s Choice
Editor's Choice
Validation of the predictive role of A.muciniphila for response and resistance to PD1 blockade in non small cell lung cancers
Editor's Choice
Did you miss Probiota Copenhagen 2022? Catch up now!
With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: […]
Editor's Choice
A new strategy for editing DNA within microbial communities using CRISPR-Cas9 technology
Benjamin Rubin was a post-doc in the lab of Jennifer Doudna—a Nobel-prize-winning scientist who pioneered CRISPR-Cas9—when a colleague got him thinking about a microbial ecology problem. He started to wonder: could it be possible to […]
In Case you Missed it:
Pharma & Human Health
Pherecydes Pharma Announces the First International Approval of a Compassionate Treatment With Its Phages
Pherecydes Pharma, a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, announces the first international approval of a compassionate treatment with its phages, in Sweden. The Swedish Medical Products […]
Finance
Xbiome Acquires Clinical-Stage Program from Assembly Biosciences Targeting Ulcerative Colitis
Xbiome Inc., an industry leading AI driven microbiome therapeutics company, today announced that it has acquired the clinical-stage M201 program from Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus […]
Pharma & Human Health
Genetics affects functions of gut microbiome
New research from Cornell scientists is exploring how human genetics impacts functions of the gut microbiome, and is expanding awareness of the role human genetics plays in shaping the microbiome. The trillions of individual organisms […]
Pharma & Human Health
Protecting the human intestinal microbiome with synthetic biology
A research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Massachusetts Institute of Technology (MIT), using a synthetic biology approach, has developed an engineered live biotherapeutic product (eLBP) that, when […]
Editor's Choice
Editor's Choice
Did you miss Probiota Copenhagen 2022? Catch up now!
With 400 registered and 60 people on the waiting list, this edition of Probiota, the first in-person since 2020, broke all records. The event started with the best and only way it is meant to: […]
Finance
Microba Life Sciences Completes Successful IPO & Announces Partnership with Ginkgo Bioworks
Microba Life Sciences (ASX:MAP), a precision microbiome science company, commenced trading on the Australian Securities Exchange (ASX) on April 4th following the completion of an initial public offering (IPO). The IPO raised $30.0 million and […]
Finance
Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund
Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a […]
